Supira Medical, Inc., a Los Gatos, CA-based percutaneous ventricular assist device (pVAD) company, closed a $120M Series E financing round.
The round was led by new investors Novo Holdings and Qatar Investment Authority (QIA), with participation from two undisclosed strategic investors. Existing investors participated as well, including Cormorant Asset Management and The Capital Partnership (TCP), 415 Capital, AMED Ventures, PA MedTech VC fund, and Unorthodox Ventures. Additionally, Supira added Dr. Christopher Shen, Partner, Novo Holdings US to its Board of Directors.
Led by Dr. Nitin Salunke, President and CEO, Supira Medical is a clinical-stage Shifamed portfolio company focused on the development of a next-generation pVAD for use in high-risk patients undergoing interventional procedures and experiencing cardiogenic shock. To date, the Supira System has benefited 85 HRPCI patients.
The company intends to use the funds to expand its clinical programs for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS). Supira recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study (EFS), enrolling a total of 15 patients across four clinical sites. The prospective, single-arm clinical study evaluated the safety and feasibility of Supira’s innovative pVAD in patients undergoing HRPCI.
FinSMEs
26/03/2025